Skip to main content
Log in

Association of digestive organ disease with metabolic syndrome: role of adipocytokine and its molecular mechanisms

  • Clinical Review
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Recently, lifestyle-related disease due to excess nutrition and insufficient physical exercise has been increasing in developed countries, including Japan. Metabolic syndrome is related to visceral fat accumulation in individuals with upper body obesity. Adipose tissue is an endocrine organ that secretes adipocytokines such as adiponectin, leptin, and TNF-α. Obesity alters the secretion of adipocytokines, leading to insulin resistance and various other metabolic disorders. Little is known about how altered regulation of adipocytokines is related to the development and progression of digestive organ disease. Clarification of the mechanisms whereby such altered adipocytokine secretion participates in pathophysiology of digestive organ disease could lead to the development of preventive and therapeutic measures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006;580:2917–21.

    Article  PubMed  CAS  Google Scholar 

  2. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin ? Hepatology. 2004;40:46–54.

    Article  PubMed  CAS  Google Scholar 

  3. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab. 2005;90:3498–504.

    Article  PubMed  CAS  Google Scholar 

  4. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol. 2005;16:421–7.

    Article  PubMed  CAS  Google Scholar 

  5. Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol. 2005;152:111–8.

    Article  CAS  Google Scholar 

  6. Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP, et al. Increased blood glucose and insulin, body size, and indent colorectal cancer. J Natl Cancer Inst. 1999;91:1147–54.

    Article  PubMed  CAS  Google Scholar 

  7. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med. 1995;122:327–34.

    PubMed  CAS  Google Scholar 

  8. Nishii T, Kono S, Abe H, Eguchi H, Shimazaki K, Hatano B, et al. Glucose intolerance, plasma insulin levels, and colon adenomas in Japanese men. Jpn J Cancer Res. 2001;92:836–40.

    PubMed  CAS  Google Scholar 

  9. Davila JA, Morgan RO, Shaib Y, McGlynn KA, EI-Serag HB. Diabetes increased the risk of hepatocellular carcinoma in the United States: a population-based case control study. Gut. 2005;54:533–9.

    Article  PubMed  CAS  Google Scholar 

  10. EI-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiological evidence. Clin Gastroenterol Hepatol. 2006;4:369–80.

    Article  Google Scholar 

  11. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2005;100:1072–81.

    Article  PubMed  Google Scholar 

  12. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.

    Article  PubMed  CAS  Google Scholar 

  13. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46–54.

    Article  PubMed  CAS  Google Scholar 

  14. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab. 2005;90:3498–504.

    Article  PubMed  CAS  Google Scholar 

  15. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol. 2005;16:421–7.

    Article  PubMed  CAS  Google Scholar 

  16. Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol. 2005;152:113–8.

    Article  PubMed  CAS  Google Scholar 

  17. Kamada Y, Matsumoto H, Tamura S, Fukushima J, Kiso S, Fukui K, et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol. 2007;47:556–64.

    Article  PubMed  CAS  Google Scholar 

  18. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. 2003;125:1796–807.

    Article  PubMed  CAS  Google Scholar 

  19. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IFG-binding protein-3. J Natl Cancer Inst. 1999;91:620–5.

    Article  PubMed  CAS  Google Scholar 

  20. Renehan AG, Painter JE, Atkin WS, Potten CS, Shalet SM, O’Dwyer ST. High-risk colorectal adenoma and serum insulin-like growth factors. Br J Surg. 2001;88:107–13.

    Article  PubMed  CAS  Google Scholar 

  21. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004;127:1044–50.

    Article  PubMed  CAS  Google Scholar 

  22. Saito K, Inoue S, Saito T, Kiso S, Ito N, Tamura S, et al. Augmentation effect of postprandial hyperinsulinemia on growth of human hepatocellular carcinoma. Gut. 2002;51:100–4.

    Article  PubMed  CAS  Google Scholar 

  23. Otake S, Takeda H, Suzuki Y, Fukui T, Watanabe S, Ishihama K, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res. 2005;11:3642–6.

    Article  PubMed  CAS  Google Scholar 

  24. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men. J Natl Cancer Inst. 2005;97:1688–94.

    Article  PubMed  CAS  Google Scholar 

  25. Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab. 2003;88:993–7.

    Article  PubMed  CAS  Google Scholar 

  26. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003;9:5699–704.

    PubMed  CAS  Google Scholar 

  27. Mantozoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004;89:1102–7.

    Article  CAS  Google Scholar 

  28. Frezza EE, Wachtel MS, Chiriva-Internati M. Influence of obesity on the risk of developing colon cancer. Gut. 2006;55:285–91.

    Article  PubMed  CAS  Google Scholar 

  29. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642–6.

    Article  PubMed  CAS  Google Scholar 

  30. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, et al. A serine/threonine kinase defective in Peutz- Jeghers sundrome. Nature. 1998;391:184–7.

    Article  PubMed  CAS  Google Scholar 

  31. Hardie DG, Hawley SA, Scott JW. AMP-activated protein development of the energy sensor concept. J Physiol. 2006;574:7–15.

    Article  PubMed  CAS  Google Scholar 

  32. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005;18:283–93.

    Article  PubMed  CAS  Google Scholar 

  33. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. Science. 2006;312:1650–3.

    Article  PubMed  CAS  Google Scholar 

  34. Vogelstein B, Kinzler KW. Cancer genes and the pathway they control. Nat Med. 2004;10:789–99.

    Article  PubMed  CAS  Google Scholar 

  35. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell. 2005;120:483–95.

    Article  PubMed  CAS  Google Scholar 

  36. Hervouet E, Demont J, Pecina P, Vojtísková A, Houstek J, Simonnet H, et al. A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial phosphorylation comples biogenesis. Carcinogenesis. 2005;26:531–9.

    Article  PubMed  CAS  Google Scholar 

  37. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288–95.

    Article  PubMed  CAS  Google Scholar 

  38. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 2004;428:569–74.

    Article  PubMed  CAS  Google Scholar 

  39. Wu L, Liu J, Gao P, Nakamura M, Cao Y, Shen H, et al. Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation. EMBO J. 2005;24:2391–402.

    Article  PubMed  CAS  Google Scholar 

  40. Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: Etiologic evidence and biological mechanisms. J Nutr. 2002;132:3456S–64S.

    PubMed  CAS  Google Scholar 

  41. IARC Working group: body weight and physical inactivity. IARC handbook of cancer prevention, vol 6. Lyon: IARC; 2002.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sumio Kawata.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kawata, S. Association of digestive organ disease with metabolic syndrome: role of adipocytokine and its molecular mechanisms. Clin J Gastroenterol 1, 1–6 (2008). https://doi.org/10.1007/s12328-008-0001-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12328-008-0001-8

Keywords

Navigation